A Post-Authorization Safety Study (Pass) to Characterize Safety Events and Special Conditions, Such as Pregnancy and Infant Outcomes, in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Crovalimab Within the IPIG Registry First published 07/08/2025 Last updated 07/08/2025 EU PAS number:EUPAS1000000702 Study Planned